Aadi Bioscience was acquired by Kaken Pharmaceutical Co., Ltd., a Japan-based pharmaceutical enterprise. Following the transaction, the clinical-stage oncology company underwent a strategic corporate evolution, eventually relaunching its clinical identity as Whitehawk Therapeutics to pursue advanced antibody-drug conjugate developments and targeted cancer therapies.